SEntine Lymph Node in earLY Ovarian Cancer (SELLY)
Launched by FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS · Jun 19, 2018
Trial Information
Current as of July 21, 2025
Completed
Keywords
ClinConnect Summary
Patients with early stage ovarian cancer have a good prognosis. However, nearly 15% of the initially diagnosed as early stage ovarian cancers, will be upstaged after an appropriate surgical staging due to lymphatic metastasis, despite of preoperative radiological data. Therefore, complete pelvic and para-aortic lymphadenectomy in these patients represents a crucial procedure. On the other hand, nodal dissection may be associated with threatening intra- and post-operative complications.
If feasible and accurate, the sentinel lymph node procedure could be a modality to avoid unnecessary radi...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Epithelial ovarian cancer
- • Early stage disease limited to the ovary
- Exclusion Criteria:
- • Evidence of extraovarian disease
- • Allergy to the materials used
About Fondazione Policlinico Universitario Agostino Gemelli Irccs
Fondazione Policlinico Universitario Agostino Gemelli IRCCS is a leading research and healthcare institution based in Rome, Italy, renowned for its commitment to advancing medical science and improving patient care. As a prominent academic medical center affiliated with the Catholic University of the Sacred Heart, it integrates clinical practice, education, and research, fostering innovation in various fields of medicine. The foundation conducts a wide range of clinical trials aimed at developing new therapies and enhancing treatment protocols, with a focus on translational research that bridges the gap between laboratory discoveries and patient care. Its multidisciplinary approach and dedication to high ethical standards position it as a key player in the landscape of clinical research and healthcare improvement in Italy and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Roma, , Italy
Biella, , Italy
Campobasso, , Italy
Roma, , Italy
Rome, , Italy
Patients applied
Trial Officials
Giovanni Scambia, MD
Principal Investigator
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials